Cambrex plans to invest SEK 72 million ($9 million) to expand large-scale manufacturing capacity for active pharmaceutical ingredients (API) at its facility in Karlskoga, Sweden.

The investment includes the installation of new multi-purpose reactors ranging from 4 cubic meters to 12 cubic meters and upgrading of the control room within an existing plant on site. The new facilities will undergo validation and cGMP qualification ahead of the operational startup in the fourth quarter of 2016. This extra capacity increases the large-scale manufacturing capabilities of the Karlskoga facility, which supports clients' development projects from R&D through to large-scale commercial manufacturing.

The expansion at Cambrex's Swedish site is part of an ongoing strategic campaign to invest in small-molecule API manufacturing across the company’s global network. In July 2016, the company announced that it had completed and validated a $50-million production and warehousing expansion for API manufacturing at its cGMP site in Charles City, Iowa. Cambrex's Charles City, Iowa facility sits on a 45-acre site and manufactures a range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances.

Source: Cambrex